Aarey Drugs & Pharmaceuticals Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Mar 2026 is 75.27% vs -48.61% in Mar 2025

Standalone Net Profit

YoY Growth in quarter ended Mar 2026 is 231.91% vs -78.14% in Mar 2025

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 203.33% vs -189.66% in Mar 2025

Interest

YoY Growth in quarter ended Mar 2026 is 36.92% vs 225.00% in Mar 2025

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Aarey Drugs With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

189.47

0.00

189.47

Other Operating Income

0.00

1.29

-1.29

-100.00%

Total Operating income

189.47

1.29

188.18

14,587.60%

Raw Material Cost

179.30

0.00

179.30

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.10

0.00

0.10

Employee Cost

0.29

1.25

-0.96

-76.80%

Power Cost

0.00

Manufacturing Expenses

-0.01

0.00

-0.01

Selling and Distribution Expenses

3.63

0.00

3.63

Other Expenses

1.82

57.27

-55.45

-96.82%

Total Expenditure (Excl Depreciation)

185.13

58.52

126.61

216.35%

Operating Profit (PBDIT) excl Other Income

4.34

-57.23

61.57

107.58%

Other Income

-0.43

6.29

-6.72

-106.84%

Operating Profit (PBDIT)

3.91

-50.94

54.85

107.68%

Interest

1.78

5.90

-4.12

-69.83%

Exceptional Items

0.00

-30.71

30.71

100.00%

Gross Profit (PBDT)

2.13

-56.84

58.97

103.75%

Depreciation

0.85

0.08

0.77

962.50%

Profit Before Tax

1.28

-56.92

58.20

102.25%

Tax

-0.28

-19.71

19.43

98.58%

Provisions and contingencies

0.00

Profit After Tax

1.56

-37.21

38.77

104.19%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

-30.71

30.71

100.00%

Net Profit

1.56

-67.92

69.48

102.30%

Equity Capital

28.45

19.43

9.02

46.42%

Face Value

10.00

1.00

0.00

Reserves

0.00

Earnings per share (EPS)

0.55

-3.50

4.05

115.71%

Diluted Earnings per share

0.55

-3.38

3.93

116.27%

Operating Profit Margin (Excl OI)

2.29%

0.00%

0.00

2.29%

Gross Profit Margin

1.12%

0.00%

0.00

1.12%

PAT Margin

0.82%

0.00%

0.00

0.82%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 189.47 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 96.48% vs 14.58% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 75.27% vs -48.61% in Mar 2025

Quarterly - Standalone Net Profit

Standalone Net Profit 1.56 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 173.68% vs -44.12% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 231.91% vs -78.14% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 4.34 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 387.42% vs -157.20% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 203.33% vs -189.66% in Mar 2025

Quarterly - Interest

Interest 1.78 Cr

in Mar 2026

Figures in Cr

QoQ Growth in quarter ended Mar 2026 is 93.48% vs -26.98% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 36.92% vs 225.00% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 2.29%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025